Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mr. Rubinson is no longer involved with MOP .. the last time I spoke with him on the phone, he informed me that neither him nor Wayne could answer anymore questions about the company. Just stating this for information sake...
Yada .. yada .. yada … That is not news,it is just a line from Charles’s play book .. Have been hearing that same story for over 10 years… Sell something !
Or maybe not ...
After being in this for so long. Hate to admit that UPTICK is correct.. But these guys write now, are just more of the same .. They have a good story line going , but so did Charles,, Hopeful they are what they say , and are truly getting the sales .
They can give speeches all day long ..share price is the reality.
Correct ..but as little as they paid for those shares and in the large sum’s they received .. selling at share prices I believe of around .03 , could have already made them a great deal. But yes I am hopeful that they are honest business people and are working to increase share price for all.. Remember in the stock world someone is going to lose so that someone else can profit
I’m just of a different opinion on that … they are a manufacturing company with stocks on the OTC board .. they make profit from selling product not from you and I trading shares back and forth.
But I do believe this.. If they do well enough to stay in business and make some profit .. as sad as it is to say, somewhere there will be another oil spill, and share prices well once again shut up .. I’m a long so my shares are put away for those kind of events.
Not sure.. Personally I believe they are concentrating on sales and realize that will take care of everything else.
From what I'm understanding ,the merger did not cost JPO that much money, but they will benefit greatly if and only if mop does well. IMO
GeoVax CEO Interviewed on the Fox Business Network
Watch Robert McNally Discuss GeoVax's Ebola Vaccine Program
ATLANTA, GA, October 30, 2014 – Robert T. McNally, PhD, President & CEO of GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, was recently interviewed on the Fox Business Network’s The Willis Report and on MONEY with Melissa Francis, discussing GeoVax’s Ebola vaccine development program.
To view The Willis Report interview in its entirety, please visit the following link: http://www.foxbusiness.com/on-air/willis-report/videos#p/157870/v/3861534177001
To view the MONEY with Melissa Francis interview, please visit the following link: http://www.foxbusiness.com/on-air/money-with-melissa-francis/index.html#/v/3863110632001
What is so Great about GeoVax Labs, Inc. (OTCMKTS:GOVX)?
http://www.microcapdaily.com/what-is-so-great-about-geovax-labs-inc-otcmktsgovx/15223/
GeoVax Presents HIV Vaccine Clinical Trial Data
Results of HIV Immunotherapy Vaccine Trial Presented at HIVR4P Conference
ATLANTA, GA, October 29, 2014 – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D., gave an oral presentation entitled Elicitation of Immune Responses by a DNA/MVA Vaccine in ART Treated Patients in a Treatment Interruption Trial. Dr. Robinson delivered the presentation at the HIV Research for Prevention 2014: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P) conference in Cape Town, South Africa.
Dr. Robinson’s presentation focused on GeoVax’s Phase 1 trial (GV-TH-01) investigating the therapeutic potential of its DNA/MVA vaccine regimen (GOVX-B11) in HIV-infected patients, which was completed earlier in 2014. GOVX-B11 was tested for safety and immunogenicity in nine HIV-infected patients who were on antiretroviral drug therapy (ART). After completing the inoculation series, patients suspended ART for a 12-week period and were observed for their ability to control virus re-emergence in the absence of drugs. ART was re-instituted after 12 weeks, and trial participants were observed for an additional 6 months.
Strong safety data results were observed throughout the trial. In GeoVax’s final analysis of the study, the Company concluded that GOVX-B11 enhanced CD8+ T cell responses in essentially all participants and that most vaccine-elicited CD8+ T cells recognized re-emergent virus. CD8+ T cell responses are critical for the recognition and killing of cells harboring a reactivated infection. However, GOVX-B11 did not prevent viral re-emergence or control re-emergent virus to levels that minimize immune escape. Dr. Robinson noted during her presentation that the Company’s analysis of the data and observations from the trial suggest that the DNA/MVA vaccine might contribute to “cure” regimens in which participants remain on ART while being treated with a shock agent timed to reactivate latent virus at a peak vaccine response.
Based on data and observations from GV-TH-01, GeoVax is now planning an additional clinical trial to further develop its HIV immunotherapy program. Current antiretroviral therapies, though highly effective at suppressing HIV viral load, are unable to eliminate HIV infection entirely. A major challenge in the development of HIV therapeutics is the ability of HIV to persist in host cells in a latent proviral form, invisible to the immune system and inaccessible to antiretroviral drugs. In response to this problem, the NIH and other leaders in the HIV field have developed a new concept: the “shock and kill” strategy, in which patients remain on drugs while one drug (“shock agent”) is used to activate latent HIV and a second drug (“kill agent”) is used to recognize and eliminate cells that harbor the reactivated virus. A shock and kill therapy could potentially contribute to a cure for HIV. GeoVax is now planning a Phase 1b trial to evaluate the use of its DNA and MVA vaccines as an approach to a cure.
About GeoVax
GeoVax Labs, Inc. (OTCQB: GOVX) is a biotechnology company developing human vaccines using its novel DNA/MVA vaccine delivery platform. The Company’s lead development program is focused on vaccines to prevent, and treat, Human Immunodeficiency Virus (HIV) infections. Recently it has initiated a program to develop an Ebola virus vaccine. GeoVax’s unique, two component HIV vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV antibody and anti-HIV T cell immune responses. GeoVax’s DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Priming and boosting can also be done with the MVA. Both the DNA and MVA express the three major proteins of the HIV virus: Gag, Pol, and Env, and produce non-infectious virus-like particles. GeoVax’s vaccines are unique in expressing virus-like particles that display the native form of the trimeric membrane-bound HIV-1 envelope glycoprotein. Clinical trials for GeoVax’s preventive HIV vaccines have been conducted by the US National Institutes of Health-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax’s vaccines, in various doses and combinations, have been tested in close to 500 humans. GeoVax is using its MVA vaccine platform to develop a vaccine to prevent acquisition of the Ebola virus. Efforts are focused against the current epidemic version of the virus. For more information, go to www.geovax.com.
GeoVax to Present HIV Vaccine Clinical Trial Data
at HIVR4P Conference
Results of HIV Immunotherapy Vaccine Trial (GV-TH-01) to be Presented
ATLANTA, GA, October 22, 2014 – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D., will give an oral presentation at the HIV Research for Prevention 2014: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P) conference in Cape Town, South Africa. Dr. Robinson’s presentation, entitled Elicitation of Immune Responses by a DNA/MVA Vaccine in ART Treated Patients in a Treatment Interruption Trial, will be delivered on Tuesday, October 28, 2014 at 11:30am local time.
HIVR4P is the world’s first and only scientific meeting dedicated exclusively to biomedical HIV prevention research. Through both abstract and non-abstract driven sessions, the conference will support cross-fertilization between research on HIV vaccines, microbicides, PrEP, treatment as prevention and other biomedical prevention approaches, while also providing a venue to discuss the research findings, questions and priorities that are specific to advancing each modality. Conference organizers expect HIVR4P to attract between 1,200 and 1,500 leaders in HIV prevention research, programs and policy. HIVR4P will be held at the Cape Town International Convention Centre in Cape Town, South Africa, October 28-31, 2014.
Researchers begin study of Ebola vaccine in Africa
Posted: Thursday, October 9, 2014 5:41 pm | Updated: 2:46 am, Sat Oct 11, 2014
http://www.newsadvance.com/news/national/wire/researchers-begin-study-of-ebola-vaccine-in-africa/article_8d0004c0-bbd6-5219-ad32-8a77e90eef8c.html
GeoVax Chairman Interviewed on the Fox Business Network
and on Glenn Beck’s TheBlaze TV
Watch David Dodd Discuss GeoVax’s Recent Initiation of an Ebola Vaccine Program
and the Rising Threat of the Global Epidemic
ATLANTA, GA, October 9, 2014 – David Dodd, Chairman of GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, was recently interviewed on the Fox Business Network’s The Willis Report and by Dana Loesch on Glenn Beck’s digital outlet, TheBlaze TV, discussing GeoVax’s initiation of an Ebola development program and perspective on the fast-moving global epidemic.
To view the Fox Business Network interview in its entirety, please visit the following link: http://www.foxbusiness.com/on-air/willis-report/videos#p/157870/v/3818202793001
To view the interview on TheBlaze TV, please visit the following link: http://www.video.theblaze.com/media/video.jsp?content_id=36764233
GeoVax announced on October 2, 2014 that it is developing two Ebola vaccines, GOVX-E301 and GOVX-E302. Both are recombinant MVA (modified vaccinia Ankara) vaccines designed to produce non-infectious virus-like particles (VLPs) displaying the Ebola virus glycoprotein. GOVX-E301 is being developed as a single-dose vaccine for epidemic response against the ZEBOV strain of Ebola, the virus responsible for the current outbreak. GOVX-E302 is being developed for routine immunization and is designed to protect against all three versions of Ebola known to be lethal in humans.
To facilitate its Ebola vaccine development efforts, GeoVax plans to collaborate with experts at the U.S. Centers for Disease Control (CDC) in Atlanta with access to Biosafety Level 4 (BSL-4) facilities for testing vaccine responses. The Company has set a goal of having its GOVX-E301 vaccine produced and ready for use in humans within eighteen months.
About GeoVax
GeoVax Labs, Inc. (OTCQB: GOVX) is a biotechnology company developing human vaccines using its novel DNA/MVA vaccine delivery platform. The Company’s lead development program is focused on vaccines to prevent, and treat, Human Immunodeficiency Virus (HIV) infections. GeoVax’s unique, two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV antibody and anti-HIV T cell immune responses. GeoVax’s DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Both the DNA and MVA express the three major proteins of the HIV virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. GeoVax’s vaccines are unique in expressing virus-like particles that display the native form of the trimeric membrane-bound HIV-1 envelope glycoprotein. Clinical trials for GeoVax’s preventive HIV vaccines have been conducted by the US National Institutes of Health-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax’s vaccines, in various doses and combinations, have been tested in close to 500 humans. www.geovax.com.
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent HIV or Ebola infection in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
INVESTOR CONTACT
Adam S. Holdsworth
ProActive Capital Group
646.862.4607
1000 shares @ .35 pre market .. that’s interesting
GeoVax will collaborate with the Centers for Disease Control and Prevention in Atlanta
http://www.bizjournals.com/atlanta/news/2014/10/03/geovax-developing-two-ebola-vaccines.html
GeoVax Announces Initiation of Ebola Vaccine Development Program
ATLANTA, GA, October 2, 2014 – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, today announced that it has initiated a new program for the development of a safe and effective vaccine to prevent Ebola infection.
With a fast-moving epidemic threatening large populations in Africa, and no proven therapy available, an effective vaccine against Ebola is desperately needed. The GeoVax recombinant MVA platform is uniquely suited to deliver a potent and safe vaccine capable of protecting people against Ebola hemorrhagic fever. GeoVax’s Ebola vaccine development efforts will be facilitated by the Company’s close proximity to, and collaboration with, the U.S. Centers for Disease Control (CDC) in Atlanta and its experts and Biosafety Level 4 (BSL-4) facilities for testing vaccine responses against lethal hemorrhagic viruses.
Since 1976, when Ebola was first discovered, over 20 outbreaks have occurred. Ebola naturally infects animals including bats, creating a reservoir of Ebola that, like rabies, cannot be eradicated completely. An effective vaccine against Ebola would dramatically reduce the epidemic spread of infections as well as the transmission of Ebola from its natural animal hosts to humans.
GeoVax is developing two Ebola vaccines, GOVX-E301 and GOVX-E302. Both are recombinant MVA (modified vaccinia Ankara) vaccines designed to produce non-infectious virus-like particles (VLPs) displaying the Ebola virus glycoprotein. GOVX-E301 is being developed as a single-dose vaccine for epidemic response against the ZEBOV strain of Ebola, the virus responsible for the current outbreak. GOVX-E302 is being developed for routine immunization and is designed to protect against all three versions of Ebola known to be lethal in humans. GOVX-E302 is anticipated to be used in a two-dose regimen.
GeoVax’s recombinant MVA vaccines have been successfully evaluated in clinical trials against HIV, in which they have shown excellent safety and immunogenicity. Advantages of the GeoVax rMVA platform include:
• Safety: GeoVax’s rMVA vaccines have demonstrated outstanding safety in human clinical trials.
• Immunogenicity: GeoVax’s rMVA technology produces virus-like particles that raise robust immune responses.
• Durability: GeoVax’s rMVA technology raises highly durable vaccine responses, by far the most durable in the field of HIV vaccines.
• Limited Pre-existing Immunity to MVA: GeoVax’s rMVA vector is based on an attenuated smallpox virus. Following smallpox eradication in 1980, smallpox vaccinations were stopped, leaving all but the elderly unvaccinated and without pre-existing immunity.
Robert McNally, PhD, GeoVax’s President and CEO, commented, “We feel an urgency in launching this new program to develop a safe and effective Ebola vaccine. For the current epidemic, containment efforts have proven difficult to institute, accentuating the world’s lack of preparation for a runaway Ebola epidemic and the need for a vaccine. With the knowledge gained from our experience in developing HIV vaccines, we believe our MVA-vectored Ebola vaccines have the unique attributes required for success and will offer superior results over other Ebola vaccines in development. We are therefore fast tracking this program with the objective of having an ‘epidemic-ready’ GOVX-E301 vaccine available by 2016.”
“Our Ebola vaccine program is a natural extension of our MVA vaccine delivery platform,” Dr. McNally continued. “It is a complementary asset to our lead HIV vaccine program, to which we remain committed. We continue to be actively engaged in discussions with the HIV Vaccine Trials Network (HVTN) and the National Institutes of Allergy and Infectious Disease (NIAID) regarding the design of our next clinical study and various trial designs are being considered.”
About GeoVax
GeoVax Labs, Inc. (OTCQB: GOVX) is a biotechnology company developing human vaccines using its novel DNA/MVA vaccine delivery platform. The Company’s lead development program is focused on vaccines to prevent, and treat, Human Immunodeficiency Virus (HIV) infections. GeoVax’s unique, two component HIV vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV antibody and anti-HIV T cell immune responses. GeoVax’s DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Priming and boosting can also be done with the MVA. Both the DNA and MVA express the three major proteins of the HIV virus: Gag, Pol, and Env, and produce non-infectious virus-like particles. GeoVax’s vaccines are unique in expressing virus-like particles that display the native form of the trimeric membrane-bound HIV-1 envelope glycoprotein. Clinical trials for GeoVax’s preventive HIV vaccines have been conducted by the US National Institutes of Health-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax’s vaccines, in various doses and combinations, have been tested in close to 500 humans. www.geovax.com
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent HIV or Ebola infection in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
INVESTOR CONTACT
Adam S. Holdsworth
ProActive Capital Group
646.862.4607
www.ProActiveCapital.com
GeoVax's Chief Scientific Officer to Present at HIV Vaccine Conference
SmallCap Network - 44 minutes ago
http://www.smallcapnetwork.com/GeoVax-s-Chief-Scientific-Officer-to-Present-at-HIV-Vaccine-Conference/s/via/18950/article/view/p/mid/1/id/5330/
GeoVax's Chief Scientific Officer Featured as Lecturer at American Society for Microbiology Conference
Dr. Harriet Robinson Presents Virtual Lecture "Working Towards an HIV Vaccine"
September 04, 2014: 10:41 AM ET
http://money.cnn.com/news/newsfeeds/articles/marketwire/1142219.htm
GeoVax: HIV Vaccines For The Developing And Developed World
By Edison | Stock Markets | Aug 08, 2014 07:06AM GMT
http://www.investing.com/analysis/geovax:--hiv-vaccines-for-the-developing-and-developed-world-222068
PRESS RELEASE
August 7, 2014, 9:23 a.m. ET
.( GOVX ) GeoVax Reports 2014 Second Quarter Financial Results and Provides Corporate Update .
http://online.wsj.com/article/PR-CO-20140807-910698.html
GeoVax Announces Clinical Development License Agreement with Valneva SE
http://www.baystreet.ca/viewarticle.aspx?id=418726
Was close to happening in the past .. They offered us a 1 to 7 share of Silver Star Capital Holdings , but then tried doing a 1 to 100 reverse split . It actual took some pretty vocal discussions between a few shareholders and Charles to get it stopped.. So if they choose to put a date on shares that will rec. a reverse split it will make more money for family members.. I think there are to many outstanding shares for family shareholders to get enough shares on the market to make them any kind of money ,with a pump and dump.But all "IMO"
Or maybe a reverse split for all shares purchased just after BP oil spill?
http://online.wsj.com/article/PR-CO-20140716-907259.html
• PRESS RELEASE
• July 16, 2014, 9:22 a.m. ET
( GOVX GOVX ) GeoVax Awarded Small Business Innovative Research (SBIR) Grant from National Institutes of Health
http://news-headlines.info/2014/07/12/sec-halts-trade-in-cynk-over-possible-stock-manipulation-reuters/
This article was in the WSJ this weekend. Found it Interesting.
I have found it possible to call there office ,and they will reply to questions. But yes agreed, it is time for some new information.
Well, one way to look at it is ... It will be sub- pennies soon,.Maybe I will buy a few more shares
From: Jim Reck [mailto:jimreck@jpoabsorbents.com]
Sent: Tuesday, June 10, 2014 5:30 PM
Hello xxxxxxxx
Understood. But this was sponsored by JPO. Not MOP. And it is through JPO's connections and relationships in the various industries--including NASCAR, that are opening doors for MOP products.
Great things are in the works and I do feel there will be news soon.
As always, thank you for your support. And your patience.
Regards
Jim
I agree .. but ready to close this book .. Been here way toooo longgggg
Lets hope so .. In any case, it is great to hear from you SunB.. hope all is well with you and yours....
Agreed .. same story ,, look at my great product , just can’t find away to show anyone how much we are selling .Hopeful there is a different outcome this time.
It makes no difference what they tell each of us individually , we can only buy and sell between ourselves for so long. If they do not release a PR with some facts of production and sales, this will be back to sub-penny .. of course all IMO ... and just a thought,, name calling does not get anything accomplished